Literature DB >> 27197298

Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers.

Gang Chen1, Shaman Luo1,2, Shannon Kozlovich1, Philip Lazarus1.   

Abstract

BACKGROUND: The most abundant and potent carcinogenic tobacco-specific nitrosamine in tobacco and tobacco smoke is 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). In vivo, NNK is rapidly metabolized to both the (R)- and (S)-enantiomers of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), which possesses similar carcinogenic properties as NNK. The major detoxification pathway for both NNAL enantiomers is glucuronidation by UDP-glucuronosyltransferase (UGT) enzymes including UGT2B10 and UGT2B17. The goal of the present study was to directly examine the role of UGT genotypes on urinary levels of NNAL glucuronides in smokers.
METHODS: NNAL-N-Gluc, (R)-NNAL-O-Gluc, (S)-NNAL-O-Gluc, and free NNAL were simultaneously and directly quantified in the urine of smokers by LC/MS analysis. Genotypes were determined by TaqMan assay using genomic DNA.
RESULTS: The functional knockout polymorphism in the UGT2B10 gene at codon 67 (Asp>Tyr) was significantly (P < 0.0001) associated with a 93% decrease in creatinine-adjusted NNAL-N-Gluc. The polymorphic whole-gene deletion of the UGT2B17 gene was associated with significant (P = 0.0048) decreases in the levels of creatinine-adjusted (R)-NNAL-O-Gluc, with a 32% decrease in the levels of urinary (R)-NNAL-O-Gluc/(S)-NNAL-O-Gluc among subjects with the UGT2B17 (*2/*2) genotype as compared to subjects with the UGT2B17 (*1/*1) genotype.
CONCLUSIONS: These results suggest that functional polymorphisms in UGT2B10 and UGT2B17 are associated with a reduced detoxification capacity against NNAL and may therefore affect individual cancer risk upon exposure to tobacco. IMPACT: This is the first report to clearly demonstrate strong genotype-phenotype associations between both the UGT2B10 codon 67 Asp<Tyr genotype and urinary NNAL-N-Gluc levels and between the UGT2B17 copy number variant and urinary (R)-NNAL-O-Gluc levels in smokers. Cancer Epidemiol Biomarkers Prev; 25(7); 1175-84. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197298      PMCID: PMC5087993          DOI: 10.1158/1055-9965.EPI-15-1245

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  48 in total

1.  Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes.

Authors:  Doris Wiener; Jia-Long Fang; Nicole Dossett; Philip Lazarus
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

2.  Quantitation of urinary metabolites of a tobacco-specific lung carcinogen after smoking cessation.

Authors:  S S Hecht; S G Carmella; M Chen; J F Dor Koch; A T Miller; S E Murphy; J A Jensen; C L Zimmerman; D K Hatsukami
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

3.  Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity.

Authors:  Carla J Gallagher; Renee M Balliet; Dongxiao Sun; Gang Chen; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2010-09-01       Impact factor: 3.922

4.  Tumorigenicity and metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol enantiomers and metabolites in the A/J mouse.

Authors:  P Upadhyaya; P M Kenney; J B Hochalter; M Wang; S S Hecht
Journal:  Carcinogenesis       Date:  1999-08       Impact factor: 4.944

5.  Formation and accumulation of pyridyloxobutyl DNA adducts in F344 rats chronically treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and enantiomers of its metabolite, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol.

Authors:  Yanbin Lao; Nanxiong Yu; Fekadu Kassie; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2007-02       Impact factor: 3.739

6.  Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.

Authors:  Gang Chen; Nino E Giambrone; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2012-03       Impact factor: 2.089

7.  A tobacco-specific N-nitrosamine or cigarette smoke condensate causes neoplastic transformation of xenotransplanted human bronchial epithelial cells.

Authors:  A J Klein-Szanto; T Iizasa; S Momiki; I Garcia-Palazzo; J Caamano; R Metcalf; J Welsh; C C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

8.  Dose-response study of the carcinogenicity of tobacco-specific N-nitrosamines in F344 rats.

Authors:  D Hoffmann; A Rivenson; S Amin; S S Hecht
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

9.  Toxic and carcinogenic agents in dry and moist snuff.

Authors:  D Hoffmann; J D Adams; D Lisk; I Fisenne; K D Brunnemann
Journal:  J Natl Cancer Inst       Date:  1987-12       Impact factor: 13.506

10.  Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4.

Authors:  Doris Wiener; Daniel R Doerge; Jia-Long Fang; Pramod Upadhyaya; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2004-01       Impact factor: 3.922

View more
  8 in total

1.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

2.  Oral Dosing of Dihydromethysticin Ahead of Tobacco Carcinogen NNK Effectively Prevents Lung Tumorigenesis in A/J Mice.

Authors:  Qi Hu; Pedro Corral; Sreekanth C Narayanapillai; Pablo Leitzman; Pramod Upadhyaya; M Gerard O'Sullivan; Stephen S Hecht; Junxuan Lu; Chengguo Xing
Journal:  Chem Res Toxicol       Date:  2020-06-11       Impact factor: 3.739

3.  Role of l- and d-Menthol in the Glucuronidation and Detoxification of the Major Lung Carcinogen, NNAL.

Authors:  Shannon Kozlovich; Gang Chen; Christy J W Watson; William J Blot; Philip Lazarus
Journal:  Drug Metab Dispos       Date:  2019-10-02       Impact factor: 3.922

4.  Influence of UGT2B10 Genotype on Urinary Excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N-glucuronide by African American Smokers.

Authors:  Sharon E Murphy; Linda B von Weymarn; Marc Parenteau; Irina Stepanov; Maarit Tiirikainen; Loic LeMarchand; Sungshim L Park
Journal:  Chem Res Toxicol       Date:  2018-02-28       Impact factor: 3.739

5.  Characterization of adductomic totality of NNK, (R)-NNAL and (S)-NNAL in A/J mice, and their correlations with distinct lung carcinogenicity.

Authors:  Qi Hu; Pramod Upadhyaya; Stephen S Hecht; F Zahra Aly; Zhiguang Huo; Chengguo Xing
Journal:  Carcinogenesis       Date:  2022-03-24       Impact factor: 4.944

6.  Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism.

Authors:  Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad
Journal:  Biochem Pharmacol       Date:  2018-08-04       Impact factor: 5.858

7.  Alkylating and oxidative stresses in smoking and non-smoking patients with COPD: Implications for lung carcinogenesis.

Authors:  Ying-Ming Shih; Yuan-Jhe Chang; Marcus S Cooke; Chih-Hong Pan; Ching-Hsuan Hu; Mu-Rong Chao; Chiung-Wen Hu
Journal:  Free Radic Biol Med       Date:  2021-01-05       Impact factor: 7.376

8.  Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.

Authors:  Deepak Kumar Bhatt; Abdul Basit; Haeyoung Zhang; Andrea Gaedigk; Seung-Been Lee; Katrina G Claw; Aanchal Mehrotra; Amarjit Singh Chaudhry; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; Timothy A Thornton; Deborah A Nickerson; Erin G Schuetz; John K Amory; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.